Kalvista Pharmaceuticals

Yahoo Finance • 16 days ago

Halper Sadeh LLC is Investigating Whether KALV, THR, CECO are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 29 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 29 days ago

Top Midday Stories: Visa Shares Rise After Strong Q2 Earnings, $20 Billion Buyback Program; Robinhood Misses Q1 EPS, Revenue Targets

The Dow Jones Industrial Average and the S&P 500 Index were down, while the Nasdaq Composite was rou PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 29 days ago

Top Premarket Gainers

Waldencast (WALD) shares were up 31% in Wednesday premarket activity, a day after the company said t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach

KalVista Pharmaceuticals logo Key Points EKTERLY generated just under $50 million in revenue in slightly less than six months and has reached something over 20% of patients, with about 1,700 start forms and ~724 prescribing physicians am... Full story

Yahoo Finance • 2 months ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 2 months ago

Most and least shorted small-to-mid-cap stocks

[short sale sign] Gunter_Nezhoda Short interest across small- to mid-cap stocks highlights extreme positioning at both ends, with highly speculative micro-cap names drawing heavy bearish bets, while a separate group of lesser-followed sto... Full story

Yahoo Finance • 2 months ago

KalVista Pharmaceuticals Q4 Earnings Call Highlights

KalVista Pharmaceuticals logo Key Points KalVista's oral HAE therapy EKTERLY showed strong early commercial traction, reporting $35.4 million in Q4 and $49.1 million in net product revenue from launch through Dec. 31, 2025, with 1,702 pa... Full story

Yahoo Finance • 2 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 2 months ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 2 months ago

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • 6 months ago

Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects

Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in. On November 11, analysts at Citizens lowered their price target of the stock to $28 from $29 while reiterating a Market Perform rating. Despite th... Full story

Yahoo Finance • 7 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * Workhorse Group (WKHS [https://seekingalpha.com/... Full story

Yahoo Finance • 7 months ago

KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M

* KalVista Pharmaceuticals press release [https://seekingalpha.com/pr/20301475-kalvista-pharmaceuticals-provides-operational-update-and-reports-third-quarter-financial] (KALV [https://seekingalpha.com/symbol/KALV]): Q3 GAAP EPS of -$0.92... Full story

Yahoo Finance • 7 months ago

KalVista Pharmaceuticals Q3 2026 Earnings Preview

* KalVista Pharmaceuticals (KALV [https://seekingalpha.com/symbol/KALV]) is scheduled to announce Q3 earnings results on Tuesday, November 11th, before market open. * The consensus EPS Estimate is -$1.09 [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 8 months ago

KalVista prices upsized offering of $125M of 3.250% notes due 2031

* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) announced [https://seekingalpha.com/pr/20243780-kalvista-prices-upsized-offering-of-125_0-million-of-3_250-percent-convertible-senior-notes] on Wednesday the... Full story

Yahoo Finance • 8 months ago

KalVista to offer $110M in convertible notes; shares down 10%

* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) plans to offer $110M in convertible senior notes due 2031 via private placement. * An additional $15M in notes may be issued if initial purchasers exercise... Full story

Yahoo Finance • 9 months ago

Stocks Rally and Bond Yields Fall on Fed Rate Cut Hopes

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.66%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 9 months ago

Stocks Climb as US Labor Market Weakness Bolsters Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 9 months ago

KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss

KalVista Pharmaceuticals Inc (NASDAQ:KALV [https://www.chartmill.com/stock/quote/KALV/profile]) reported its fiscal first-quarter 2026 financial results, delivering revenue that fell short of analyst expectations while posting a wider-than... Full story